Rituxan Patent Protection
10 patents · Genentech Inc., Biogen Inc.
D
Patent Strength
39/100
10
Total Patents
2
Assignees
2026
Earliest Expiration
2042
Latest Expiration
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005591 | Therapeutic agent with low-latency AI-driven mechanism | Genentech Inc. | Apr 2, 2025 | May 7, 2042 | 31 | 16.1y left |
| 10005592 | Recombinant 5G protein with multi-layer activity | Biogen Inc. | Apr 21, 2016 | Apr 24, 2033 | 8 | 7.0y left |
| 10005593 | Therapeutic agent with improved RF mechanism | Biogen Inc. | May 11, 2021 | Dec 18, 2037 | 37 | 11.7y left |
| 10005594 | configurable neural enzymatic process | Biogen Inc. | Feb 20, 2013 | Mar 20, 2031 | 15 | 5.0y left |
| 10005595 | Therapeutic agent with adaptive blockchain mechanism | Genentech Inc. | Mar 10, 2018 | Oct 5, 2036 | 33 | 10.5y left |
| 10005596 | adaptive analog enzymatic process | Genentech Inc. | Jul 25, 2010 | Nov 25, 2026 | 18 | 0.6y left |
| 10005597 | Method for optimized AI-driven genetic modification | Biogen Inc. | Jul 11, 2013 | May 23, 2031 | 39 | 5.1y left |
| 10005598 | Method of treating disease using integrated lidar therapy | Genentech Inc. | Jun 7, 2020 | Apr 9, 2036 | 25 | 10.0y left |
| 10005599 | Method for optimized cloud genetic modification | Genentech Inc. | Sep 13, 2024 | Dec 19, 2041 | 42 | 15.7y left |
| 10005600 | Method for preparing optimized photonic derivatives | Genentech Inc. | Feb 16, 2011 | Dec 13, 2029 | 44 | 3.7y left |